Stefan A. Dyckerhoff Sells 1,000 Shares of Astera Labs, Inc. (NASDAQ:ALAB) Stock

Key Points

• Stefan A. Dyckerhoff, Director of Astera Labs, sold 1,000 shares of the company at an average price of $173.42, reducing his position by 10.06% to 8,936 shares valued at approximately $1.55 million.
• Astera Labs reported an earnings per share of $0.44 for the last quarter, exceeding analysts' forecasts, with a 149.5% year-over-year revenue growth.
• Several analysts upgraded their ratings for Astera Labs, with Evercore ISI raising its price target to $215.00, while a consensus of 14 buy ratings places the stock in a positive outlook.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) Director Stefan A. Dyckerhoff sold 1,000 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $173.42, for a total transaction of $173,420.00. Following the transaction, the director owned 8,936 shares in the company, valued at $1,549,681.12. The trade was a 10.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Astera Labs Trading Up 0.1%

NASDAQ:ALAB traded up $0.15 on Monday, hitting $179.43. 4,765,213 shares of the stock were exchanged, compared to its average volume of 6,896,421. The stock has a market cap of $29.82 billion, a PE ratio of 320.41, a PEG ratio of 7.63 and a beta of 1.39. The stock has a fifty day moving average of $107.68 and a 200-day moving average of $87.31. Astera Labs, Inc. has a fifty-two week low of $36.85 and a fifty-two week high of $185.75.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.33 by $0.11. The firm had revenue of $191.93 million during the quarter, compared to the consensus estimate of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%. Astera Labs's revenue for the quarter was up 149.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.13 earnings per share. As a group, analysts predict that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Barclays restated an "overweight" rating and set a $155.00 price target (up previously from $75.00) on shares of Astera Labs in a research report on Thursday. Evercore ISI increased their price target on shares of Astera Labs from $104.00 to $215.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. Roth Capital set a $100.00 price target on shares of Astera Labs and gave the company a "buy" rating in a research report on Wednesday, May 7th. Citigroup cut their target price on shares of Astera Labs from $120.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Finally, Northland Securities downgraded shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 price target on the stock. in a report on Tuesday, July 22nd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.13.

Institutional Trading of Astera Labs

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Astera Labs by 2,824.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 154,524 shares of the company's stock valued at $20,467,000 after acquiring an additional 149,240 shares during the period. Pacific Point Advisors LLC boosted its position in shares of Astera Labs by 75.0% in the first quarter. Pacific Point Advisors LLC now owns 7,000 shares of the company's stock worth $418,000 after buying an additional 3,000 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Astera Labs by 73.6% during the first quarter. Oppenheimer Asset Management Inc. now owns 15,995 shares of the company's stock valued at $954,000 after purchasing an additional 6,783 shares during the last quarter. Taylor Frigon Capital Management LLC acquired a new stake in Astera Labs during the first quarter valued at $1,887,000. Finally, Cetera Investment Advisers bought a new position in Astera Labs during the fourth quarter valued at about $460,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.